Published in J Neurochem on January 12, 2006
Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 1.97
Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLoS One (2010) 1.41
Does Alzheimer's disease begin in the brainstem? Neuropathol Appl Neurobiol (2009) 1.26
Is neurodegenerative disease a long-latency response to early-life genotoxin exposure? Int J Environ Res Public Health (2011) 1.14
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol (2009) 1.14
Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes (2008) 1.04
Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev (2011) 1.03
Alzheimer 100--highlights in the history of Alzheimer research. J Neural Transm (Vienna) (2006) 1.01
Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm (Vienna) (2011) 0.99
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna) (2012) 0.97
Calorie restriction reduces the influence of glucoregulatory dysfunction on regional brain volume in aged rhesus monkeys. Diabetes (2012) 0.95
Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener (2010) 0.94
Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm (Vienna) (2011) 0.94
Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease. J Alzheimers Dis (2009) 0.92
A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol (2012) 0.91
Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2009) 0.91
Glycogen synthase kinase-3 regulates production of amyloid-β peptides and tau phosphorylation in diabetic rat brain. ScientificWorldJournal (2014) 0.87
A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol (2011) 0.87
Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease. PLoS One (2012) 0.86
Modeling Alzheimer's disease with non-transgenic rat models. Alzheimers Res Ther (2013) 0.84
Neuroprotective role for galanin in Alzheimer's disease. EXS (2010) 0.83
Early failure of the default-mode network and the pathogenesis of Alzheimer's disease. CNS Neurosci Ther (2014) 0.83
Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus. Sci Rep (2015) 0.83
In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. PLoS One (2012) 0.82
The link between iron, metabolic syndrome, and Alzheimer's disease. J Neural Transm (Vienna) (2010) 0.82
Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism. Mol Neurobiol (2015) 0.81
Diabetes mellitus accelerates Aβ pathology in brain accompanied by enhanced GAβ generation in nonhuman primates. PLoS One (2015) 0.81
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease. Br J Pharmacol (2015) 0.80
Nicorandil inhibits oxidative stress and amyloid-β precursor protein processing in SH-SY5Y cells overexpressing APPsw. Int J Clin Exp Med (2015) 0.80
Mechanisms of action of brain insulin against neurodegenerative diseases. J Neural Transm (Vienna) (2014) 0.79
Alois Alzheimer revisited: differences in origin of the disease carrying his name. J Neural Transm (Vienna) (2006) 0.79
Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models. Int J Mol Sci (2016) 0.79
Effects of erythropoietin on memory deficits and brain oxidative stress in the mouse models of dementia. Korean J Physiol Pharmacol (2010) 0.79
Univ.-Prof. Dr. med. Siegfried Hoyer 1933-2014. J Neural Transm (Vienna) (2014) 0.78
Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr) (2013) 0.78
Brain catalase in the streptozotocin-rat model of sporadic Alzheimer's disease treated with the iron chelator-monoamine oxidase inhibitor, M30. J Neural Transm (Vienna) (2014) 0.78
Long-term effects of corticosterone on behavior, oxidative and energy metabolism of parietotemporal cerebral cortex and hippocampus of rats: comparison to intracerebroventricular streptozotocin. J Neural Transm (Vienna) (2008) 0.78
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78
17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner. J Neural Transm (Vienna) (2008) 0.77
Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats. Psychopharmacology (Berl) (2014) 0.76
Insulin-resistant brain state (IRBS) changes membrane composition of fatty acids in temporal and entorhinal brain cortices of rats: relevance to sporadic Alzheimer's disease? J Neural Transm (Vienna) (2010) 0.76
Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease. J Neural Transm (Vienna) (2015) 0.76
Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer's disease. J Neural Transm (Vienna) (2014) 0.76
Effects of treadmill exercise on brain insulin signaling and β-amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats. J Exerc Nutrition Biochem (2014) 0.75
Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets. Pharmaceuticals (Basel) (2009) 0.75
Luteinizing hormone downregulation but not estrogen replacement improves ovariectomy-associated cognition and spine density loss independently of treatment onset timing. Horm Behav (2015) 0.75
Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction. Psychopharmacology (Berl) (2015) 0.75
Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model. Sci Rep (2017) 0.75
Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction. J Mol Psychiatry (2015) 0.75
Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease? J Neural Transm (Vienna) (2017) 0.75
In vitro streptozotocin model for modeling Alzheimer-like changes: effect on amyloid precursor protein secretases and glycogen synthase kinase-3. J Neural Transm (Vienna) (2014) 0.75
The effects of lipoic acid on redox status in brain regions and systemic circulation in streptozotocin-induced sporadic Alzheimer's disease model. Metab Brain Dis (2017) 0.75
Cognitive impairment and gene expression alterations in a rodent model of binge eating disorder. Physiol Behav (2017) 0.75
Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science (2010) 6.29
Bruchpilot promotes active zone assembly, Ca2+ channel clustering, and vesicle release. Science (2006) 5.39
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Bruchpilot, a protein with homology to ELKS/CAST, is required for structural integrity and function of synaptic active zones in Drosophila. Neuron (2006) 5.16
Piezo proteins are pore-forming subunits of mechanically activated channels. Nature (2012) 3.54
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Pore region of TRPV3 ion channel is specifically required for heat activation. Nat Neurosci (2008) 2.13
Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry (2007) 1.93
Glutamate receptor dynamics organizing synapse formation in vivo. Nat Neurosci (2005) 1.79
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem (2005) 1.51
The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2004) 1.42
Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem (2007) 1.37
A Syd-1 homologue regulates pre- and postsynaptic maturation in Drosophila. J Cell Biol (2010) 1.33
Inflammatory signals enhance piezo2-mediated mechanosensitive currents. Cell Rep (2012) 1.32
Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). Mol Biol Cell (2006) 1.26
The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem (2011) 1.26
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci (2005) 1.23
In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord (2005) 1.23
The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett (2002) 1.22
Basic limb kinematics of small therian mammals. J Exp Biol (2002) 1.21
Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener Dis (2004) 1.21
Genes associated with Parkinson syndrome. J Neurol (2008) 1.21
A glutamate receptor-interacting protein homolog organizes muscle guidance in Drosophila. Genes Dev (2004) 1.14
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
metaXCMS: second-order analysis of untargeted metabolomics data. Anal Chem (2010) 1.10
"Subcellular proteomics" of neuromelanin granules isolated from the human brain. Mol Cell Proteomics (2005) 1.08
The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. Br J Pharmacol (2004) 1.07
Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis (2010) 1.07
Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J Neurosci (2003) 1.05
The glucocorticoid receptor gene exon 1-F promoter is not methylated at the NGFI-A binding site in human hippocampus. World J Biol Psychiatry (2007) 1.05
Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells. Exp Brain Res (2003) 1.04
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna) (2011) 1.04
Perineuronal nets potentially protect against oxidative stress. Exp Neurol (2004) 1.03
Characterization of Eag1 channel lateral mobility in rat hippocampal cultures by single-particle-tracking with quantum dots. PLoS One (2010) 1.03
Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs (2003) 1.02
HUPO Brain Proteome Project: summary of the pilot phase and introduction of a comprehensive data reprocessing strategy. Proteomics (2006) 1.02
Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int (2012) 1.01
Structure-activity relationships of flavonoid-induced cytotoxicity on human leukemia cells. Arch Biochem Biophys (2007) 1.00
Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder--a postmortem study. Psychiatry Res (2007) 1.00
The role of the metabolic lesion in Alzheimer's disease. J Alzheimers Dis (2002) 0.99
Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochem Int (2006) 0.99
Gait abnormalities differentially indicate pain or structural joint damage in monoarticular antigen-induced arthritis. Pain (2009) 0.99
Redox imbalance. Cell Tissue Res (2004) 0.98
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna) (2012) 0.97
Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology (2007) 0.96
Non-NMDA-type glutamate receptors are essential for maturation but not for initial assembly of synapses at Drosophila neuromuscular junctions. J Neurosci (2006) 0.96
Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol (2003) 0.95
Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism Relat Disord (2007) 0.94
Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis (2009) 0.94
Cultivation in glucose-deprived medium stimulates mitochondrial biogenesis and oxidative metabolism in HepG2 hepatoma cells. Biol Chem (2002) 0.94
Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm (Vienna) (2011) 0.94
The Bruchpilot cytomatrix determines the size of the readily releasable pool of synaptic vesicles. J Cell Biol (2013) 0.93
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology. World J Biol Psychiatry (2015) 0.93
Dolichol is the major lipid component of human substantia nigra neuromelanin. J Neurochem (2005) 0.93
Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm (Vienna) (2010) 0.92
Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. J Neural Transm (Vienna) (2012) 0.91
Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease. J Neurovirol (2007) 0.90
Oxidative stress in the brain at early preclinical stages of mouse scrapie. Exp Neurol (2006) 0.90
Rapid microarray processing using a disposable hybridization chamber with an integrated micropump. Lab Chip (2012) 0.90
Complex interaction of Drosophila GRIP PDZ domains and Echinoid during muscle morphogenesis. EMBO J (2006) 0.90
Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor. Planta Med (2003) 0.89
Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J Psychiatr Res (2008) 0.89
Functional neurochemistry of Alzheimer's disease. Curr Pharm Des (2004) 0.89
Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem (2005) 0.89
Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother (2013) 0.89
Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis (2009) 0.88
Reduced thermal hyperalgesia and enhanced peripheral nerve injury after hind paw inflammation in mice lacking the serotonin-transporter. Eur J Pain (2008) 0.88
Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach. Mol Cell Proteomics (2009) 0.88
Torque patterns of the limbs of small therian mammals during locomotion on flat ground. J Exp Biol (2002) 0.88
Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res (2003) 0.88
Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the World Federation of ADHD. World J Biol Psychiatry (2012) 0.87
Therapeutic drug monitoring of antidepressants in haemodialysis patients. Clin Drug Investig (2012) 0.87
Drosophila mutants of the kynurenine pathway as a model for ageing studies. Adv Exp Med Biol (2003) 0.87
Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport (2003) 0.87
Alzheimer disease--no target for statin treatment. A mini review. Neurochem Res (2006) 0.87
Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study. Parkinsons Dis (2012) 0.86
Effects of methylphenidate: the cellular point of view. Atten Defic Hyperact Disord (2010) 0.85
Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. J Alzheimers Dis (2007) 0.85
Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) in the putamen of individuals with Alzheimer's disease: a human postmortem study. J Alzheimers Dis (2010) 0.84
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci (2005) 0.84
Reduced brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus. Neurochem Res (2007) 0.84
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm (Vienna) (2013) 0.84
Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol (2009) 0.84
PMCA2 via PSD-95 controls calcium signaling by α7-containing nicotinic acetylcholine receptors on aspiny interneurons. J Neurosci (2012) 0.83
Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. J Alzheimers Dis (2006) 0.83
Neuromelanin is an immune stimulator for dendritic cells in vitro. BMC Neurosci (2011) 0.83
The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J Neurovirol (2007) 0.82
The link between iron, metabolic syndrome, and Alzheimer's disease. J Neural Transm (Vienna) (2010) 0.82
Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychiatry (2010) 0.82